Literature DB >> 23483513

Preservative-free treatment in glaucoma: who, when, and why.

Ingeborg Stalmans1, Gordana Sunaric Mégevand, M Francesca Cordeiro, Anton Hommer, Luca Rossetti, Francisco Goñi, Anders Heijl, Alain Bron.   

Abstract

PURPOSE: To review and summarize the available literature on the effect of preservatives on the eye, to provide practical guidance for the clinical assessment of the ocular surface in glaucoma patients, and to define patient populations that might benefit from preservative-free topical intraocular pressure (IOP)-lowering agents.
METHODS: This manuscript is based on a combination of a literature review on preservatives and the eye and expert opinion from glaucoma specialists with an interest in ocular surface disease.
RESULTS: There is an increasingly recognized association between eyedrop preservatives and ocular surface disease. Preservative-free therapy is now available for a wide range of active compounds, although there are still some misconceptions regarding their appropriate use. For patients treated topically for glaucoma or ocular hypertension, a rough estimate could be that 20% may need treatment with topical IOP-reducing agents that are free from preservatives.
CONCLUSION: This review provides an up-to-date account of the literature regarding preservatives and the eye, as well as suggestions and recommendations on to when to use preservative-free antiglaucoma treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23483513     DOI: 10.5301/ejo.5000270

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  13 in total

1.  [Preservative-free glaucoma treatment : Selection of the correct treatment in 1 min].

Authors:  S Pfennigsdorf; P Eschstruth
Journal:  Ophthalmologe       Date:  2016-05       Impact factor: 1.059

2.  Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial.

Authors:  Ingeborg Stalmans; Francesco Oddone; Maria Francesca Cordeiro; Anton Hommer; Giovanni Montesano; Luisa Ribeiro; Gordana Sunaric-Mégevand; Luca Rossetti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-24       Impact factor: 3.117

3.  Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies.

Authors:  Kai Kaarniranta; Kirsi Ikäheimo; Eliisa Mannermaa; Auli Ropo
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

Review 4.  Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.

Authors:  Gábor Holló; Andreas Katsanos; Kostas G Boboridis; Murat Irkec; Anastasios G P Konstas
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

5.  Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis.

Authors:  Paul Harasymowycz; Cindy Hutnik; Jean-François Rouland; Francisco J Muñoz Negrete; Mario A Economou; Philippe Denis; Christophe Baudouin
Journal:  Adv Ther       Date:  2021-04-23       Impact factor: 3.845

6.  Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study.

Authors:  Fernando Pérez-Roca; Esther Rodrigo-Morales; Ingrid Garzón; Ana-Celeste Oliveira; Miguel-Ángel Martín-Piedra; Víctor Carriel; Ana-Isabel Ortiz-Pérez; Indalecio Sánchez-Montesinos; Antonio Campos; Miguel Alaminos
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

7.  A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients.

Authors:  Paolo Fogagnolo; Angelica Dipinto; Elisa Vanzulli; Emanuele Maggiolo; Stefano De Cilla'; Alessandro Autelitano; Luca Rossetti
Journal:  Adv Ther       Date:  2015-04-19       Impact factor: 3.845

8.  Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice.

Authors:  Stefan Pfennigsdorf; Peter Eschstruth; Stefan Häsemeyer; Cord Feuerhake; Gerrett Brief; Ioana Grobeiu; Andrew Shirlaw
Journal:  Clin Ophthalmol       Date:  2016-09-20

9.  Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study.

Authors:  Yoshihiko Esaki; Atsushi Shimazaki; Pertti Pellinen
Journal:  Open Ophthalmol J       Date:  2016-05-31

10.  Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice.

Authors:  Lutz E Pillunat; Peter Eschstruth; Stefan Häsemeyer; Ulrich Thelen; Christian Foja; Richard Leaback; Stefan Pfennigsdorf
Journal:  Clin Ophthalmol       Date:  2016-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.